In the most important prospective randomized controlled trials primarily evaluating the cardiovascular safety of incretin-based therapy, an increased risk of pancreatic cancer was not observed in patients treated with incretins compared to controls [108, 109]. Here, GCG is linked to familial pancreatic carcinoma.